Research in the Robert Lawrence Lab examines how industrial agriculture, food security and human rights affect the environment.

Work in the Sean Berenholtz Lab focuses on patient safety, ICU care, quality health care and evidence-based medicine. Two notable and successful projects include the National On The Cusp: Stop BSI project, which was implemented in 47 states with the goal of eliminating bloodstream infections, and the Agency for Healthcare Research and Quality (AHRQ)-funded Keystone ICU project, which improved communication and teamwork and reduced hospital-acquired infections in more than 100 ICUs in Michigan. One recent study focused on ventilator-associated pneumonia (VAP), one of the most common type of health care-associated infections in the ICU. Existing VAP prevention intervention bundles vary widely on the interventions, but our research team described a structured approach for developing a new VAP prevention bundle.

Work in the Pedro Alejandro Mendez-Tellez Lab focuses on critical care medicine and acute lung injury. Recent studies include evaluating demographic and clinical factors associated with self-reported dysphagia after oral endotracheal intubation and mechanical ventilation in patients with acute lung injury. We've also analyzed orticosteroids and their relationship with delirium in critically ill patients.

The Bradford Winters Lab conducts research on patient safety and quality of care. Our team focuses on the topics of patient care in the intensive care unit, evidence-based medicine, quality health care, and the measurement and evaluation of safety efforts. Currently our work involves evaluating pain management techniques in post-craniotomy patients, developing guidelines for policy development of patient safety initiatives and creating measures for rapid-response system outcomes.

The Paul Worley Lab examines the molecular basis of learning and memory. In particular, we cloned a set of immediate early genes (IEGs) that are rapidly transcribed in neurons involved in information processing, and that are essential for long term memory. IEG proteins can directly modify synapses and provide insight into cellular mechanisms that support synapse-specific plasticity.

The Pluznick Lab is interested in the role that chemosensation plays in regulating physiological processes, particularly in the kidney and the cardiovascular system. We have found that sensory receptors (olfactory receptors, taste receptors, and other G-protein coupled receptors) are expressed in the kidney and in blood vessels, and that individual receptors play functional roles in whole-animal physiology. We are currently working to identify the full complement of sensory receptors found in the kidney, and are working to understand the role that each receptor plays in whole-animal physiology by using a variety of in vitro (receptor localization, ligand screening) and in vivo (whole-animal physiology) techniques.

The Post Lab is involved in the Multi-Ethnic Study of Atherosclerosis (MESA), a collaborative study of the characteristics of subclinical cardiovascular disease (that is, disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. As MESA researchers, we study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Approximately 38 percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United States, including Johns Hopkins University. Each participant received an extensive physical exam to determine a number of conditions, including coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits have allowed study of the progression of disease. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. Wendy S. Post, MD, MS, is an associate faculty, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, and a professor of medicine.

Research in the Peter Abadir Lab focuses on the renin-angiotensin system (RAS), a signaling pathway that regulates blood pressure and has been linked independently to both aging and inflammation. We’re particularly interested in changes in RAS that occur with aging. We also study signal transduction and the role of the crosstalk between angiotensin II receptor in aging and are interested in understanding the function of angiotensin II in the process of vascular aging.

Dr. Williams' research focuses on platelet physiology particularly as it relates to acute coronary syndromes and depression. Her laboratory specifically examines platelet aggregation, flow cytometric analysis to measure platelet activation, platelet luminescence as a measure of the platelet release reaction, many Elisa preparations in order to measure platelet function, platelet genotyping to determine the presence of certain platelet polymorphisms, and various other assays to distinguish mechanisms of platelet dysfunction. The goal for her cardiovascular platelet laboratory is to identify the etiology of platelet dysfunction in many disease states and apply methods that may improve this dysfunction that can eventually be translated to therapies for patients with cardiovascular disease. Scientific techniques performed in the lab include: flow cytometric analysis, platelet microparticle identification, and protein immunoprecipitation among other techniques.

The Philip Wong Lab seeks to understand the molecular mechanisms and identification of new therapeutic targets of neurodegenerative diseases, particularly Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Taking advantage of discoveries of genes linked to these diseases (mutant APP and PS in familial AD and mutant SOD1, dynactin p150glued ALS4and ALS2 in familial ALS), our laboratory is taking a molecular/cellular approach, including transgenic, gene targeting and RNAi strategies in mice, to develop models that facilitate our understanding of pathogenesis of disease and the identification and validation of novel targets for mechanism-based therapeutics. Significantly, these mouse models are instrumental for study of disease mechanisms, as well as for design and testing of therapeutic strategies for AD and ALS.